baseline were -2.8 (0.3) kg in the exenatide 5-pg  group (P = 0.004) and -3.1 (0.3) kg in the exenatide  10-pg group (P < 0.001) compared with -1.4 (0.3) kg  with placebo (Figure 5).  HOMA-B  HOMA-B values were comparable across treatment  groups at baseline, with geometric means of 45.3 to  50.0. These values increased from baseline to end  point by 32% and 28% in the exenatide 5- and 10-pg  groups, respectively, versus 6% for placebo. Improve-  ments from baseline to end point in HOMA-B were  August 2008 1453